Bleakley Financial Group LLC Has $4.20 Million Holdings in Danaher Corporation (NYSE:DHR)

Bleakley Financial Group LLC cut its stake in shares of Danaher Corporation (NYSE:DHRFree Report) by 0.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,477 shares of the conglomerate’s stock after selling 195 shares during the period. Bleakley Financial Group LLC’s holdings in Danaher were worth $4,198,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. FAS Wealth Partners Inc. raised its position in shares of Danaher by 20.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate’s stock valued at $2,203,000 after buying an additional 1,639 shares in the last quarter. Horizon Financial Services LLC raised its position in shares of Danaher by 20,400.0% in the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate’s stock valued at $1,681,000 after buying an additional 8,160 shares in the last quarter. Vision Capital Management Inc. acquired a new stake in shares of Danaher in the first quarter valued at approximately $461,000. Compass Wealth Management LLC raised its position in shares of Danaher by 17.4% in the first quarter. Compass Wealth Management LLC now owns 39,764 shares of the conglomerate’s stock valued at $8,152,000 after buying an additional 5,891 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Danaher by 11.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate’s stock valued at $1,303,163,000 after buying an additional 579,046 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of Danaher stock opened at $197.69 on Tuesday. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $281.70. The stock has a market cap of $141.48 billion, a price-to-earnings ratio of 38.39, a P/E/G ratio of 2.88 and a beta of 0.77. The company’s fifty day moving average is $196.06 and its 200 day moving average is $205.89.

Danaher (NYSE:DHRGet Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.26. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. Sell-side analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.65%. Danaher’s dividend payout ratio is 24.85%.

Insider Buying and Selling at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the company’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Scotiabank upgraded shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target for the company in a research report on Friday. Wolfe Research lowered their price objective on shares of Danaher from $275.00 to $220.00 and set an “outperform” rating for the company in a research report on Monday, April 7th. Royal Bank Of Canada restated an “outperform” rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. The Goldman Sachs Group lowered their price objective on shares of Danaher from $260.00 to $240.00 and set a “neutral” rating for the company in a research report on Wednesday, April 23rd. Finally, Barclays restated an “overweight” rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $248.43.

Read Our Latest Stock Report on DHR

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Further Reading

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.